{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:27Z","timestamp":1793317587143,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bone.2019.115150","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T02:32:02Z","timestamp":1573266722000},"page":"115150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1892-7264","authenticated-orcid":false,"given":"Liana","family":"Tripto-Shkolnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naama","family":"Fund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Rouach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varda","family":"Shalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5317-2848","authenticated-orcid":false,"given":"Inbal","family":"Goldshtein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bone.2019.115150_bb0005","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bone.2019.115150_bb0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"12","key":"10.1016\/j.bone.2019.115150_bb0015","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"Journal of Bone and Mineral Research\u202f: The Official Journal of the American Society for Bone and Mineral Research"},{"issue":"8","key":"10.1016\/j.bone.2019.115150_bb0020","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2019.115150_bb0025","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.bone.2019.115150_bb0030","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","volume":"28","author":"Uebelhart","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2019.115150_bb0035","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"Journal of Bone and Mineral Research\u202f: The Official Journal of the American Society for Bone and Mineral Research"},{"issue":"3","key":"10.1016\/j.bone.2019.115150_bb0040","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/jbmr.3370","article-title":"Underestimation of vertebral fractures after denosumab discontinuation","volume":"33","author":"Lamy","year":"2018","journal-title":"Journal of Bone and Mineral Research\u202f: The Official Journal of the American Society for Bone and Mineral Research"},{"issue":"2","key":"10.1016\/j.bone.2019.115150_bb0045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","author":"Lamy","year":"2016","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"5","key":"10.1016\/j.bone.2019.115150_bb0050","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab\u2014from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2019.115150_bb0055","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12020-016-1030-6","article-title":"Clinical vertebral fractures following denosumab discontinuation","volume":"54","author":"Polyzos","year":"2016","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.bone.2019.115150_bb0060","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporosis International\u202f: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA"},{"issue":"5","key":"10.1016\/j.bone.2019.115150_bb0065","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","article-title":"Multiple clinical vertebral fractures following denosumab discontinuation","volume":"27","author":"Anastasilakis","year":"2016","journal-title":"Osteoporosis International\u202f: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA"},{"issue":"3","key":"10.1016\/j.bone.2019.115150_bb0070","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1210\/jc.2016-3781","article-title":"Letter to the editor: severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report","volume":"102","author":"Trovas","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bone.2019.115150_bb0075","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"Journal of Bone and Mineral Research\u202f: The Official Journal of the American Society for Bone and Mineral Research"},{"issue":"1","key":"10.1016\/j.bone.2019.115150_bb0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","article-title":"Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates","volume":"103","author":"Tripto-Shkolnik","year":"2018","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"10.1016\/j.bone.2019.115150_bb0085","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","article-title":"Cancel the denosumab holiday","volume":"27","author":"McClung","year":"2016","journal-title":"Osteoporosis International\u202f: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA"},{"issue":"6","key":"10.1016\/j.bone.2019.115150_bb0090","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1530\/EJE-16-1027","article-title":"Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment","volume":"176","author":"Anastasilakis","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2019.115150_bb0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.maturitas.2017.04.016","article-title":"Bisphosphonates or denosumab discontinuation and risk of fractures","volume":"102","author":"Anastasilakis","year":"2017","journal-title":"Maturitas"},{"issue":"2","key":"10.1016\/j.bone.2019.115150_bb0100","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"Journal of Bone and Mineral Research\u202f: The Official Journal of the American Society for Bone and Mineral Research"},{"key":"10.1016\/j.bone.2019.115150_bb0105","series-title":"Fracture Risk After Discontinuation of Denosumab","author":"Sprafka","year":"2016"},{"issue":"1","key":"10.1016\/j.bone.2019.115150_bb0110","article-title":"Osteoporosis in the community: findings from a novel computerized registry in a large health organization in Israel","volume":"4","author":"Goldshtein","year":"2015","journal-title":"Journal of Aging Research & Clinical Practice"},{"issue":"2","key":"10.1016\/j.bone.2019.115150_bb0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650070214","article-title":"Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989","volume":"7","author":"Cooper","year":"1992","journal-title":"Journal of Bone and Mineral Research\u202f: The Official Journal of the American Society for Bone and Mineral Research"},{"issue":"2","key":"10.1016\/j.bone.2019.115150_bb0120","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2019.115150_bb0125","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2019.115150_bb0130","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/jbmr.3654","article-title":"Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT extension I trials","volume":"34","author":"Kim","year":"2019","journal-title":"Journal of Bone and Mineral Research\u202f: The Official Journal of the American Society for Bone and Mineral Research"},{"issue":"4","key":"10.1016\/j.bone.2019.115150_bb0135","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00198-018-4791-3","article-title":"A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk","volume":"30","author":"Nayak","year":"2019","journal-title":"Osteoporosis International\u202f: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA"},{"issue":"7","key":"10.1016\/j.bone.2019.115150_bb0140","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate drug holiday and fracture risk: a population-based cohort study","volume":"33","author":"Adams","year":"2018","journal-title":"Journal of Bone and Mineral Research\u202f: The Official Journal of the American Society for Bone and Mineral Research"},{"issue":"4","key":"10.1016\/j.bone.2019.115150_bb0145","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/1060028015626935","article-title":"Cost and consequences of nonadherence with oral bisphosphonate therapy: findings from a real-world data analysis","volume":"50","author":"Sharman Moser","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bone.2019.115150_bb0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219304442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219304442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T19:36:13Z","timestamp":1611862573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219304442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":30,"alternative-id":["S8756328219304442"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.115150","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.115150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115150"}}